Birmingham's Queen Elizabeth Hospital Cancer Centre manages significant CML and GIST patient populations across the West Midlands. Generic Imatib 400mg provides Birmingham patients with affordable access to this life-transforming tyrosine kinase inhibitor, which converted CML from a fatal disease into a manageable chronic condition for most patients.
The development of Imatinib is considered one of the greatest successes of targeted cancer therapy, demonstrating that identifying and blocking a cancer's specific molecular driver can achieve outcomes far superior to conventional chemotherapy with vastly less toxicity. Birmingham's haematology patients benefit from this landmark medicine at reduced cost.
The development of Imatinib is considered one of the greatest successes of targeted cancer therapy, demonstrating that identifying and blocking a cancer's specific molecular driver can achieve outcomes far superior to conventional chemotherapy with vastly less toxicity. Birmingham's haematology patients benefit from this landmark medicine at reduced cost.
What happens if CML becomes resistant to Imatib — are there other treatment options?If a CML patient develops resistance to Imatinib (Imatib), typically detected by rising BCR-ABL levels on molecular monitoring, there are excellent second-line options. Second-generation TKIs including Dasatinib and Nilotinib are effective against most Imatinib-resistant BCR-ABL mutations. Third-generation Ponatinib is used for the most resistant mutation (T315I). Treatment-free remission attempts are also possible after achieving deep molecular remission on any TKI. The availability of multiple TKI generations means CML is now a highly manageable chronic condition with good long-term outcomes even when resistance to one agent develops.
